Torrent Pharma posts 21% rise in Q1 net profit

AHMEDABAD: Homegrown pharma major, Torrent Pharmaceuticals Limited (Torrent Pharma) reported a 21% increase in consolidated net profit for the June quarter (Q1 FY 2024-25) to Rs 457 crore, up from Rs 378 crore in the year-ago period. The company’s revenue from operations rose to Rs 2,859 crore in Q1 FY25, a 10% growth.

The company reported that its India business witnessed a year-on-year growth of 10% in the June quarter, with revenue reaching Rs 1,635 crore from Rs 1,426 crore reported in Q1 FY24, backed by outperformance in focus therapies.

Torrent Pharma in the USA market were down by 12% at Rs 259 crore, falling from Rs 293 crore reported in Q1 FY24. However, its revenues from the Brazil market marginally increased by 3% during the quarter to Rs 196 crore. “Primary sales in the Brazil market were impacted by severe floods in the Rio Grande do Sul province in April and May this year,” states Torrent Pharma.

The pharma giant’s chronic business grew at 14% during the quarter, driven by a strong revival in cardiac divisions and continued traction in anti-diabetes new launches, the company said.